Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 8/20 | 0.48 |
| ▸ | RAB9A | P51151 | 8/20 | 0.48 |
| ▸ | POLB | P06746 | 4/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.44 |
| ▸ | MAPT | P10636 | 6/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | NSD2 | O96028 | 1/20 | 0.41 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.41 |
| ▸ | USP2 | O75604 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 3/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
| ▸ | PPARG | P37231 | 1/20 | 0.34 |
| ▸ | PPARA | Q07869 | 1/20 | 0.34 |
| ▸ | BRD4 | O60885 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9418498 | 0.83 | NPC1 (0.43) | NPC1RAB9APOLBLMNAALDH1A1 | |
| SCHEMBL1263238 | 0.82 | NPC1 (0.62) | NPC1RAB9APOLBLMNAALDH1A1 | |
| SCHEMBL8301562 | 0.81 | LIG1 (0.42) | NPC1RAB9APOLBLMNAALDH1A1 | |
| SCHEMBL1264001 | 0.79 | NPC1 (0.45) | NPC1RAB9APOLBLMNAALDH1A1 | |
| SCHEMBL17212261 | 0.79 | NPC1 (0.43) | NPC1RAB9APOLBLMNAALDH1A1 | |
| SCHEMBL1263210 | 0.76 | NPC1 (0.42) | NPC1RAB9APOLBLMNAALDH1A1 | |
| SCHEMBL12196763 | 0.73 | KDM4E (0.52) | NPC1RAB9APOLBLMNAALDH1A1 | |
| SCHEMBL9418500 | 0.72 | ALDH1A1 (0.37) | NPC1RAB9APOLBLMNAALDH1A1 | |
| SCHEMBL10546687 | 0.70 | NPC1 (0.62) | NPC1RAB9APOLBLMNAALDH1A1 | |
| SCHEMBL2472876 | 0.69 | NPC1 (0.53) | NPC1RAB9APOLBLMNAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130274286-A1 | NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE (NMPRTase) INHIBITOR FOR GLIOMA THERAPY | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) | 2013-10-17 | — | — | US | claimed |
| EP-2552444-A1 | NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE (NMPRTase) INHIBITOR FOR GLIOMA THERAPY | Council of Scientific & Industrial Research (IN) | 2013-02-06 | — | — | EP | claimed |
| WO-2011121434-A1 | NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE (NMPRTase) INHIBITOR FOR GLIOMA THERAPY | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2011-10-06 | — | — | WO | claimed |
| EP-2552444-B1 | NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE (NMPRTase) INHIBITOR FOR GLIOMA THERAPY | COUNCIL SCIENT IND RES (IN) | 2018-10-10 | — | — | EP | disclosed |
| US-9335332-B2 | Nicotinamide phosphoribosyltransferase (NMPRTase) inhibitor for glioma therapy | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) | 2016-05-10 | — | — | US | disclosed |
| US-9335332-B2 | Nicotinamide phosphoribosyltransferase (NMPRTase) inhibitor for glioma therapy | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) | 2016-05-10 | — | — | US | disclosed |
| US-9335332-B2 | Nicotinamide phosphoribosyltransferase (NMPRTase) inhibitor for glioma therapy | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) | 2016-05-10 | — | — | US | disclosed |
| US-20130274286-A1 | NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE (NMPRTase) INHIBITOR FOR GLIOMA THERAPY | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) | 2013-10-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130274286-A1 | NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE (NMPRTase) INHIBITOR FOR GLIOMA THERAPY | NAMPT, NAPRT, NMT1 | NPC1 1226/4885RAB9A 2693/4885POLB 2369/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.